2-year, Randomized, Double-blind, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone Versus Placebo in Combination with Glipizide in Elderly Patients with Type 2 Diabetes Mellitus who are Inadequately Controlled on Glipizide Therapy
Diabetes Mellitus, Type 2
Phase 3
A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
February 2015